Harvard Bioscience Swings to Loss Amid Rising Costs

TL;DR

HBIO's revenue growth is overshadowed by ballooning expenses, making it a risky bet for the short term.

AI Summary

HARVARD BIOSCIENCE INC (HBIO) reported a mixed financial performance for the six months ended June 30, 2025. Revenue from continuing operations increased to $55.2 million, up from $52.8 million in the prior year period, representing a 4.5% growth. However, the company experienced a net loss from continuing operations of $2.5 million for the six months ended June 30, 2025, a significant decline from the net income of $1.2 million reported in the same period of 2024. This shift was primarily driven by increased operating expenses, including a rise in research and development expenses to $6.8 million from $6.1 million, and general and administrative expenses to $12.5 million from $11.8 million. Selling and marketing expenses also saw an increase to $10.2 million from $9.8 million. The company also incurred employee severance costs of $0.3 million in Europe and North America during the first six months of 2025, compared to $0.2 million in 2024. The strategic outlook remains focused on operational efficiency, but the increased expenses are impacting profitability.

Why It Matters

This shift from profit to loss for HARVARD BIOSCIENCE INC signals potential headwinds for investors, suggesting that revenue growth isn't translating to improved bottom-line performance. Employees might face increased scrutiny on departmental spending as the company navigates profitability challenges. For customers, this could imply a focus on cost-cutting measures that might impact product development or service levels, potentially affecting HBIO's competitive standing against rivals in the laboratory analytical instruments sector. The broader market will be watching to see if these cost pressures are industry-wide or specific to HBIO's operational structure.

Risk Assessment

Risk Level: medium — The company's shift from a net income of $1.2 million in the first six months of 2024 to a net loss of $2.5 million in the same period of 2025 indicates a deteriorating financial performance. This is further evidenced by rising operating expenses, with R&D increasing by $0.7 million, G&A by $0.7 million, and S&M by $0.4 million, outpacing revenue growth of $2.4 million.

Analyst Insight

Investors should exercise caution and closely monitor HBIO's next earnings report for signs of expense control and a return to profitability. Consider holding off on new investments until there's clear evidence of improved operational efficiency and a positive net income trend.

Financial Highlights

revenue

$55.2M

net Income

-$2.5M

revenue Growth

+4.5%

Key Numbers

• $55.2M — Revenue from continuing operations (Increased from $52.8 million in 2024, a 4.5% growth.)
• -$2.5M — Net loss from continuing operations (A significant decline from $1.2 million net income in 2024.)
• $6.8M — Research and Development Expense (Increased from $6.1 million in 2024.)
• $12.5M — General and Administrative Expense (Increased from $11.8 million in 2024.)
• $10.2M — Selling and Marketing Expense (Increased from $9.8 million in 2024.)
• $0.3M — Employee Severance Costs (Incurred in Europe and North America, up from $0.2 million in 2024.)

Key Players & Entities

• HARVARD BIOSCIENCE INC (company) — filer of the 10-Q
• Bloomberg (company) — publisher of the analysis
• SEC (regulator) — regulator for 10-Q filings
• Europe and North America (person) — geographic region where severance costs were incurred
• Holliston, MA (person) — business address location

FAQ

Industry Context

Harvard Bioscience Inc. operates in the laboratory analytical instruments sector. This industry is characterized by innovation and the need for continuous research and development to meet the evolving demands of scientific research and diagnostics. Companies in this space often face competition from both established players and emerging technology firms.

Regulatory Implications

As a publicly traded company, Harvard Bioscience Inc. is subject to SEC regulations, including timely and accurate financial reporting through filings like the 10-Q. Compliance with accounting standards and disclosure requirements is crucial to maintain investor confidence and avoid penalties.

What Investors Should Do

1. Monitor the impact of increased operating expenses (R&D, G&A, S&M) on future profitability. Investors should look for signs of cost control or revenue growth acceleration to offset these increases.
2. Evaluate the company's strategy for improving operational efficiency. The stated focus on efficiency needs to translate into improved net income in subsequent reporting periods.
3. Assess the sustainability of revenue growth. While revenue increased by 4.5%, the concurrent rise in expenses leading to a net loss requires careful scrutiny of the underlying drivers of both.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document is the 10-Q filing for Harvard Bioscience Inc., detailing their financial results for the period ending June 30, 2025.)

Continuing Operations

Refers to revenue and expenses from business activities that are expected to continue into the future, as opposed to discontinued operations. (The net loss is specifically attributed to continuing operations, highlighting the core business's profitability challenges.)

Employee Severance Costs

Expenses incurred by a company when terminating employees, often including payments for unused vacation, benefits, and outplacement services. (An increase in these costs in Europe and North America contributed to the overall rise in operating expenses.)

Year-Over-Year Comparison

Compared to the prior year period, Harvard Bioscience Inc. has seen a modest revenue increase of 4.5% to $55.2 million. However, this top-line growth has been overshadowed by a significant deterioration in profitability, with the company reporting a net loss of $2.5 million compared to a net income of $1.2 million in the same period last year. This shift is primarily driven by increased operating expenses across R&D, G&A, and Selling & Marketing, along with higher severance costs.

Key Financial Figures

• $0.01 — ange on which registered Common Stock, $0.01 par value HBIO The Nasdaq Global Ma

Filing Documents

• hbio20250630_10q.htm (10-Q) — 1353KB
• ex_845412.htm (EX-31.1) — 17KB
• ex_845413.htm (EX-31.2) — 12KB
• ex_845414.htm (EX-32.1) — 4KB
• ex_845415.htm (EX-32.2) — 4KB
• logo.jpg (GRAPHIC) — 6KB
• 0001171843-25-005287.txt ( ) — 7371KB
• hbio-20250630.xsd (EX-101.SCH) — 71KB
• hbio-20250630_def.xml (EX-101.DEF) — 421KB
• hbio-20250630_lab.xml (EX-101.LAB) — 353KB
• hbio-20250630_pre.xml (EX-101.PRE) — 472KB
• hbio-20250630_cal.xml (EX-101.CAL) — 53KB
• hbio20250630_10q_htm.xml (XML) — 1341KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION 1

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations 2 Condensed Consolidated Statements of Comprehensive Loss 3 Condensed Consolidated Statements of Stockholders' Equity 4 Condensed Consolidated Statements of Cash Flows 5 Notes to Condensed Consolidated Financial Statements 6

Management ' s Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management ' s Discussion and Analysis of Financial Condition and Results of Operations 18

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 24

Controls and Procedures

Item 4. Controls and Procedures 24

- OTHER INFORMATION

PART II - OTHER INFORMATION 25

Legal Proceedings

Item 1. Legal Proceedings 25 Item1A. Risk Factors 25

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 26

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 26

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 26

Other Information

Item 5. Other Information 26

Exhibits

Item 6. Exhibits 27

SIGNATURES

SIGNATURES 28 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements. HARVARD BIOSCIENCE, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited, in thousands, except share and per share data) June 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 7,442 $ 4,108 Accounts receivable, net 11,937 14,866 Inventories 22,255 23,245 Other current assets 3,335 2,898 Total current assets 44,969 45,117 Property, plant and equipment, net 4,913 5,106 Operating lease right-of-use assets 7,131 6,132 Goodwill 10,152 56,324 Intangible assets, net 9,139 11,132 Other long-term assets 3,789 2,833 Total assets $ 80,093 $ 126,644 Liabilities and Stockholders' Equity Current liabilities: Debt $ 34,864 $ 36,956 Accounts payable 4,722 4,787 Contract liabilities 3,143 3,806 Other current liabilities 12,473 9,409 Total current liabilities 55,202 54,958 Deferred tax liability 734 710 Operating lease liabilities 6,997 6,381 Other long-term liabilities 1,427 1,255 Total liabilities 64,360 63,304 Commitments and contingencies - Note 13 Stockholders' equity: Preferred stock, par value $ 0.01 per share, 5,000,000 shares authorized - - Common stock, par value $ 0.01 per share, 80,000,000 shares authorized: 44,531,198 shares issued and outstanding at June 30, 2025; 44,074,475 shares issued and outstanding at December 31, 2024 445 441 Additional paid-in-capital 237,622 236,579 Accumulated deficit ( 210,632 ) ( 158,010 ) Accumulated other comprehensive loss ( 11,702 ) ( 15,670 ) Total stockholders' equity 15,733 63,340 Total liabilities and stockholders' equity $ 80,093 $ 126,644 See accompanying notes to condensed consolidated financial statements. 1 Table of Contents HARVARD BIOSCIENCE, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, in thousands, except per share data) Three Months Ended June 30, Six Months Ended June 30,

View Full Filing

View this 10-Q filing on SEC EDGAR